Summer Street does not expect the Food and Drug Administration to approve Mannkind Corp.'s (Nasdaq: MNKD) inhalable insulin product Afrezza. Shares of the biopharmaceutical dropped 75 cents to $4.07.
Summer Street Expects Mannkind's Afrezza To Be Rejected
March 31, 2014 at 14:26 PM EDT
